MilliporeSigma

Maximal conservative therapy of calcific uremic ateriolopathy.

Clinical nephrology (2012-06-27)
Charlotte Van Noten, Karin Janssen van Doorn, Evert Vermander, Sonja Vlayen, Gert A Verpooten, Marie-Madeleine Couttenye
ABSTRACT

We present the case of a 61-year- old female patient in long-term hemodialysis who developed calcific uremic arteriolopathy (CUA) upon administration of the oral calcimimetic agent cinacalcet for treatment of secondary hyperparathyroidism. In May 2009, the baseline serum values were parathormone (PTH) 310 pg/ml, calcium 9.1 mg/dl and phosphorous 6.9 mg/dl. Necrotic wounds in the suprapubic fat tissue were successfully treated first, by correcting the calcium phosphorous product; second, through treatment with sodium thiosulfate and third, through intensive wound care with hyperbaric oxygen therapy and vacuum-assisted closure therapy, with no need for parathyroidectomy. Multiple factors have been described to play a role in the development of CUA. Based on the findings of this case, the treatment of CUA should be aimed at correcting different causes simultaneously.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Sodium thiosulfate pentahydrate, BioXtra, ≥99.5%
Sigma-Aldrich
Sodium thiosulfate pentahydrate, 99.999% trace metals basis
Sigma-Aldrich
Sodium thiosulfate pentahydrate, ACS reagent, ≥99.5%
Sigma-Aldrich
Sodium thiosulfate pentahydrate, puriss., meets analytical specification of Ph. Eur., BP, USP
Sigma-Aldrich
Sodium thiosulfate pentahydrate, ReagentPlus®, ≥99.5%
Sigma-Aldrich
Sodium thiosulfate, ≥99.99% trace metals basis
Sigma-Aldrich
Sodium thiosulfate, purum p.a., anhydrous, ≥98.0% (RT)
Sigma-Aldrich
Sodium thiosulfate, ReagentPlus®, 99%